Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US
Shots:
- Biocon Biologics has entered into strategic collaboration agreement with Civica to extend access & affordability of Insulin Aspart in the US
- As per the deal, Biocon will supply Insulin Aspart drug substance to Civica, which will manufacture prefilled pens & vials of insulin at its Petersburg, Virginia facility. Civica will commercialize it in the US post-development & trials, with no technology transfer involved
- Additionally, Biocon's insulin aspart drug product is under the US FDA review
Ref: Biocon Biologics & Civica | Image: Biocon Biologics & Civica
Related News:- Biocon Biologics Launches Yesintek (Biosimilar, Stelara) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
